Evidence map›Paper›PMID 35545834›Full record

ArticleBrain tumor research and treatment2022

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report.

Takayuki Morimoto, Ryosuke Matsuda, Tsutomu Nakazawa, Fumihiko Nishimura, Ichiro Nakagawa

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takayuki MorimotoDepartment of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.ORCID https://orcid.org/0000-0002-9974-3538
Ryosuke MatsudaDepartment of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan. rmatsuda@naramed-u.ac.jp.ORCID https://orcid.org/0000-0002-0307-3657
Tsutomu NakazawaDepartment of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.ORCID https://orcid.org/0000-0003-4286-9356
Fumihiko NishimuraDepartment of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
Ichiro NakagawaDepartment of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.ORCID https://orcid.org/0000-0002-1340-3293
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brainstem gliomas are not common in adults, and the treatment strategies and their outcomes are limited. Immunotherapy is emerging as a promising new modality for the treatment of these gliomas. Here, we report the first case of brainstem glioma treated with a combination of radiotherapy and autologous formalin-fixed tumor vaccine (AFTV). A 32-year-old man presented with left facial numbness and right hemiparesis, and was referred to our department. MRI and open biopsy indicated brainstem glioma, and he was specifically diagnosed with isocitrate dehydrogenase 1-mutant diffuse astrocytoma of WHO grade II. He was treated with stereotactic radiotherapy followed by AFTV three months later. MRI conducted at 42 months after the combination therapy showed a 91% decrease in tumor volume, and the regression was maintained for 5 years. Thus, combination treatment with radiotherapy and immunotherapy may prove to be a promising alternative for the treatment of brainstem glioma.

Indexed as

AstrocytomaCancer vaccineGliomaImmunotherapyRadiotherapy

Identifiers

PMID35545834
PMCPMC9098982
OpenAlexW4280538240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.